Cytisine-platinum(IV) prodrug-1

Cytisine-Platinum(IV) Prodrug-1 是一种掺入天然产物 Cytisine (MS-R91146) 的 Pt(IV) 前药,对肿瘤细胞具有抗增殖活性,可促进钙离子通过 IP3R1-GRP75-VDAC1 轴转运以引发线粒体钙超载,通过 PERK、eIF2α、ATF4 和 CHOP 启动未折叠蛋白反应并调控 Bcl-2 和 Bax 从而触发细胞凋亡 (apoptosis),同时可诱导线粒体功能障碍、活性氧 (ROS) 产生、ATP 合成减少、DNA 损伤以及 S 期细胞周期阻滞,并激活 cGAS-STING 通路、降低 PD-L1 表达、驱动免疫原性细胞死亡;此外,该化合物具有较高的生理稳定性、高效的细胞蓄积能力和增强的铂-DNA 结合能力,并在小鼠模型中抑制肿瘤生长且降低全身毒性,可用于肺癌研究。
Cytisine-platinum(IV) prodrug-1
产品编号: MS-K37549 分子式: C29H51Cl2N5O6Pt 分子量: 831.74
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Cytisine-Platinum(IV) Prodrug-1 是一种掺入天然产物 Cytisine (MS-R91146) 的 Pt(IV) 前药,对肿瘤细胞具有抗增殖活性,可促进钙离子通过 IP3R1-GRP75-VDAC1 轴转运以引发线粒体钙超载,通过 PERK、eIF2α、ATF4 和 CHOP 启动未折叠蛋白反应并调控 Bcl-2 和 Bax 从而触发细胞凋亡 (apoptosis),同时可诱导线粒体功能障碍、活性氧 (ROS) 产生、ATP 合成减少、DNA 损伤以及 S 期细胞周期阻滞,并激活 cGAS-STING 通路、降低 PD-L1 表达、驱动免疫原性细胞死亡;此外,该化合物具有较高的生理稳定性、高效的细胞蓄积能力和增强的铂-DNA 结合能力,并在小鼠模型中抑制肿瘤生长且降低全身毒性,可用于肺癌研究。

生物实验数据

生物活性 Cytisine-Platinum(IV) Prodrug-1 is a Pt(IV) prodrug incorporating the natural product Cytisine (MS-R91146) that exhibits antiproliferative activity against tumor cells, promotes calcium transport through the IP3R1-GRP75-VDAC1 axis to induce mitochondrial calcium overload, initiates the unfolded protein response via PERK, eIF2α, ATF4, and CHOP and regulates Bcl-2 and Bax to trigger apoptosis, and induces mitochondrial dysfunction, reactive oxygen species (ROS) production, reduced ATP synthesis, DNA damage, and S-phase cell cycle arrest, while activating the cGAS-STING pathway, decreasing PD-L1 expression, and driving immunogenic cell death; furthermore, it possesses high physiological stability, efficient cellular accumulation, and enhanced platinum-DNA binding capacity, and inhibits tumor growth with reduced systemic toxicity in mouse models, making it applicable for lung cancer research.
IC50 & Target

eIF2

 

Bcl-2

 

Bax

 

体外研究
(In Vitro)

Cytisine-Platinum(IV) Prodrug-1 (Compound CP12) (72 h) 可强效抑制 H226、SW1990、HepG2 及 MDA-MB-231 肿瘤细胞的活力,其 IC50 值为 0.09、0.15、0.21 和 0.61 μM,同时相较于正常 PUMC-HUVEC-T1 细胞,该化合物对肿瘤细胞具有高选择性。
Cytisine-Platinum(IV) Prodrug-1 (100 μM; 12-72 h) 在 37 °C 条件下在 PBS、RPMI-1640 培养基及大鼠血浆中均表现出高稳定性。
Cytisine-Platinum(IV) Prodrug-1 (100 μM; 16 h) 会在 H226 细胞内发生还原性活化,释放金雀花碱衍生物 CYT-COOH。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可强效抑制 H226 细胞的集落形成,并可有效杀伤 H226 细胞。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可强效抑制 H226 细胞的迁移和凋亡。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 12 h) 可在 H226 细胞中诱导强烈的 S 期细胞周期阻滞,使 62.19% 的细胞停滞于 S 期,并降低 cyclin D1 的表达。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可诱导 H226 细胞发生内质网应激,激活 IP3R1-GRP75-VDAC1 轴,并引发线粒体钙超载,这一过程与其抗肿瘤活性相关。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可诱导 H226 细胞发生线粒体功能障碍,表现为 ATP 生成减少、MMP 崩溃、ROS 生成增加、细胞色素 C 释放及线粒体形态破坏。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可激活 H226 细胞中的 cGAS-STING 通路,上调通路关键蛋白并促进 IL-6 分泌。
Cytisine-Platinum(IV) Prodrug-1 (1 μM; 24 h) 可在 H226 细胞中强效诱导免疫原性细胞死亡,其特征为 CRT 暴露增加、HMGB1、LDH 和 ATP 释放增加,以及 PD-L1 表达降低。

Cell Migration Assay

Cell Line: H226
Concentration: 1 μM
Incubation Time: 24 h
Result: Drastically suppressed H226 cell migration, resulting in a wound healing rate of only 2.44%.

Apoptosis Analysis

Cell Line: H226
Concentration: 1 μM
Incubation Time: 24 h
Result: Induced a high rate of apoptosis in H226 cells, with an apoptosis rate of 80.4%.

Cell Cycle Analysis

Cell Line: H226
Concentration: 1 μM
Incubation Time: 12 h
Result: Resulted in significant S-phase cell cycle arrest in H226 cells, with 62.19% of cells in S phase, and complete blockage of transition from S to G2 phase.
Reduced cyclin D1 protein expression.

Western Blot Analysis

Cell Line: H226
Concentration: 1 μM
Incubation Time: 24 h
Result: Significantly upregulated protein expression of p-PERK, p-eIF2α, ATF4, and CHOP, while downregulating Bcl-2 and upregulating Bax.
Upregulated expression of IP3R1, GRP75, and VDAC1, key components of the ER-mitochondria calcium transfer axis.
Resulted in a significant increase in both cytosolic and mitochondrial Ca2+ levels.
Pretreatment with 2-APB reduced Ca2+ accumulation in the cytosol and mitochondria, and partially reversed CP12-induced cytotoxicity.

Western Blot Analysis

Cell Line: H226
Concentration: 1 μM
Incubation Time: 24 h
Result: Significantly upregulated protein expression of cGAS, p-STING, p-IRF3, and p-TBK1, indicating activation of the cGAS-STING pathway.
Induced the highest level of IL-6 secretion among tested compounds, with levels 2.14-fold higher than those induced by CDDP.

Immunofluorescence

Cell Line: H226
Concentration: 1 μM
Incubation Time: 24 h
Result: Significantly increased CRT surface exposure and HMGB1 release, and reduced PD-L1 protein expression in H226 cells.
体内研究
(In Vivo)

Cytisine-Platinum(IV) Prodrug-1 (Compound CP12) (2-4 mg/kg Pt;每 3 天 1 次;共给药 6 次) 可强效抑制裸鼠体内 H226 肺癌肿瘤的生长,无明显肝肾毒性,对体重的影响极小。
Cytisine-Platinum(IV) Prodrug-1 (2-4 mg/kg Pt;静脉注射;每 3 天 1 次,共给药 6 次) 可强效抑制免疫健全小鼠体内 LLC 肺癌的肿瘤生长;同时该药物可激活 cGAS-STING 通路,诱导免疫原性细胞死亡,并增强细胞毒性 T 细胞浸润以重塑肿瘤微环境。

Animal Model: BALB/c nude (male, 4-6 weeks old, 18 g, H226 cell-derived xenograft model)
Dosage: 2, 4 mg/kg Pt
Administration: i.v.; once every 3 days; 6 total doses
Result: Achieved a tumor growth inhibition (TGI) rate of 59.3%.
Achieved a tumor growth inhibition (TGI) rate of 72.7%.
Showed no significant body weight loss, with the low-dose group having body weight comparable to the control group, and the high-dose group showing an increasing body weight trend.
Caused no remarkable abnormalities in liver, lung, or kidney tissue.
Achieved significantly higher platinum accumulation in tumor tissue and lower platinum accumulation in renal tissue compared to CDDP (MS-E94993).
Induced a concentration-dependent increase in necrotic area in tumor tissue.
Animal Model: C57BL/6 (male, 5 weeks old, 18 g, LLC cell-derived xenograft model)
Dosage: 2, 4 mg/kg Pt
Administration: i.v.; once every 3 days; 6 total doses
Result: Achieved a tumor growth inhibition (TGI) rate of 69.1%.
Achieved a tumor growth inhibition (TGI) rate of 81.1%.
Showed no significant body weight loss.
Potently activated the cGAS-STING pathway in tumor tissue in a dose-dependent manner.
Significantly increased calreticulin (CRT) exposure and high mobility group box 1 (HMGB1) release in tumor tissue.
Substantially increased infiltration of CD3+ and CD8+ T cells in tumors compared to control and CDDP groups.

化学信息

分子量 831.74
分子式 C29H51Cl2N5O6Pt

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础